fbpx Skip to main content

BioCommunique Article

Bringing you the latest financial and strategic news from top leaders in life science.

Bayer Fronts $65M Series A for Metagenomi, UCB Acquires Handl Therapeutics, Adagio Therapeutics Raises $80M in Series B

  • 2020-11-12T20:00:00.000+0000
  • California
  • Author: Lauren Panetta

11/12/20 – Atara Biotherapeutics

Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)

11/12/20 – Metagenomi

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

11/12/20 – Fierce Biotech

UCB inks Handl buyout to boost nascent gene therapy unit

11/12/20 – eFFECTOR Therapeutics

eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer® (SU2C) Canada

11/12/20 – Trefoil Therapeutics

Trefoil Therapeutics Wins ‘People’s Choice’ Award at Eyecelerator Conference

11/11/20 – MyoKardia

MyoKardia Collaborates with the American College of Cardiology and PINNACLE/Veradigm to Launch Patient Registry of Hypertrophic Cardiomyopathy

11/11/20 – Inhibrx

Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

11/11/20 – Nektar Therapeutics

Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

11/10/20 – Fierce Biotech

Adagio, 'firing on all cylinders,' grabs $80M for COVID-19 antibody

11/10/20 – aTyr Pharma

aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline

11/10/20 – Renew Biopharma

Renew Biopharma and Algae-C Announce License Agreement for Best-in-Class Engineered Enzymes

11/10/20 – Bolt Biotherapeutics

Bolt Biotherapeutics Presents BDC-1001 Ongoing Clinical Trial Design and Supportive Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting

11/9/20 – Arena Pharmaceuticals

Arena Pharmaceuticals Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports Compelling Topline Results from Phase 2b ADVISE Trial

11/9/20 – Sorrento Therapeutics

Sorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2

11/9/20 – Passage Bio

Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1

11/9/20 – Ultragenyx

Ultragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Facility to Support Pipeline of Therapies for Rare Diseases

11/9/20 NuVasive

NuVasive’s Thoracolumbar Interbody Portfolio Receives First Clearance in the US for the Treatment of Sagittal Deformities

11/9/20 – Arcturus Therapeutics

Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore

11/9/20 – Prometheus Biosciences

Prometheus Biosciences Announces $130 Million Financing to Advance Precision Medicines for the Treatment of Inflammatory Bowel Disease

11/9/20 – HUYA Bioscience International

HUYA Bioscience International Presents Positive Data On HBI-8000 at Society for Immunotherapy of Cancer Meeting

11/6/20 – Ligand

Ligand's Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT for the Treatment of Status Epilepticus in Adult and Pediatric Patients

11/6/20 – Vir Biotechnology

Vir Biotechnology Publishes New Research Characterizing Variation in the SARS-CoV-2 Spike Protein and Virulence of a Prevalent Immune Evasion Variant, N439K

11/5/20 – BioWorld

Merck’s multibillion-dollar oncology deals continue with Velosbio acquisition